FDAapproval54% confidence
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
Source: FDA
Why This Matters
Why this matters: sets a approval precedent in the same sub-indication (melanoma) as Novartis.
Regulatory Analysis
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.
Supporting Context
- Therapeutic area
- Oncology · BRAF/MEK Inhibitors
- Sub-indication
- Melanoma
Related signal: Dabrafenib and Trametinib Rollover Study for Continued Patient Access